LHRC Revenue & Doctor Analytics

Total Revenue

₹397 Cr

ADR ₹1.09 Cr/day

IP Revenue

₹298 Cr

75.0% of total · 20,932 disc

ARPP-IP

₹1.42 L

ALOS 4.47d · ARPOB ₹31,875

IP Discharges

20,932

93,495 bed days · Kochi

OP Revenue

₹99 Cr

3,48,861 visits · ₹2,844/visit

Key Person Risk

TOP 5

= 45.0% of all revenue

🚨 Critical Finding: Revenue Concentration — Priority #1

2 doctors (Gangadharan VP + Abi Abraham M) generate ₹108.8 Cr = 27.4% of total hospital revenue. Top 5 doctors = 45.0% of revenue. This is the single biggest operational risk — loss of either top doctor would trigger a ₹50–55 Cr revenue shock with no immediate mitigation path.

Revenue by Department — Top 15 (₹ Crore, FY24)

Nephrology + Medical Oncology = 30.3% of total revenue

Revenue Mix

IP ₹298 Cr · OP ₹99 Cr · Pharmacy ₹34 Cr

IP Revenue

₹298 Cr

OP Revenue

₹99 Cr

Pharmacy

₹34 Cr

Registration

₹7.3 Cr

Top 12 Doctors by Revenue (₹ Crore, FY24)

Top 12 = 63.6% of all doctor revenue

Revenue Concentration Curve (Lorenz)

X = cumulative doctor count · Y = % of total revenue

Department Performance Table — All 22 Departments

Click column headers to sort. ALOS computed from bed utilisation. Pharma/Diag are estimates.

#	Department	Total ₹Cr	% Share	IP ₹Cr	OP ₹Cr	Pharma ₹Cr	Diag ₹Cr	IP Disc.	OP Visits	ARPP-IP	ARPP-OP	ARPOB	ALOS	Docs	Tier

Revenue Composition by Department — IP · OP · Pharma · Diagnostics

Pharma and Diagnostics are estimates based on specialty benchmarks

Top 6 Department Doctor Breakdowns

Medical Oncology

Nephrology

GI Surgery

Neuro Surgery

Gastroenterology

Cardiology

Filter:

#	Doctor	Department	Total ₹Cr	% Hosp	IP ₹Cr	OP ₹Cr	Discharges	Bed Days	OP Visits	ARPP-IP	ARPOB	ARPP-OP	BCG

🚨 Concentration Risk — FY24 Verified Figures

Top 2 doctors (Gangadharan VP + Abi Abraham M): ₹109.0 Cr = 27.5% of hospital revenue | Top 5 doctors: ₹180.3 Cr = 45.4% of revenue | 80% revenue threshold: reached at Top 24 doctors out of 177 | Single-doctor depts: Medical Oncology (Gangadharan 100%), Urology (George P Abraham 100%), Min. Invasive Surgery (Padmakumar 100%), CT Surgery (Sujith 100%), Psychiatry (Xavier Pulikkal 100%)

Revenue Concentration — Pareto (Doctors)

Red dashed line = 80% cumulative threshold · Top 24 of 177 doctors = 80% of revenue

Single-Doctor Dependency by Department

% of dept IP revenue from top-1 doctor. Red > 70% = critical risk · 10 of 15 major depts are single-doctor dependent

Revenue-at-Risk — Top 5 Doctor Departure Scenario

Estimated annual revenue impact if doctor were to leave

Department Depth Index (Multi-Doctor Resilience)

Score = 10 − (top doctor % / 10). Higher = more resilient

X-Axis: Y-Axis:

Volume vs ARPP-IP — Department Portfolio Matrix

Bubble size = total revenue. Axes = median lines. Quadrant = BCG category

⭐ Stars — High Volume + High ARPP-IP

💠 Premium — Low Volume + High ARPP-IP

💰 Cash Cows — High Volume + Low ARPP-IP

❓ Question Marks — Low Volume + Low ARPP-IP

Monthly Revenue — IP vs OP (₹ Crore, FY24)

IP typically 73-75% of monthly revenue. Peak in March (Q4).

Top 5 Departments — Monthly IP Revenue Trend

Proportional allocation from monthly IP totals

IP Discharge & Bed Occupancy — Monthly

Discharge count (left axis) vs Occupancy % (right axis)

Estimated Payor Mix — FY24

Cash dominant at 73.3% (₹291 Cr). Insurance 22.2% (₹88 Cr) — significantly underpenetrated vs peers (Apollo 45%).

ARPP-OP by Department (₹ per visit)

Computed from OP Revenue / OP Visits. All in ₹ per visit.

ARPOB by Department (₹ per occupied bed day)

Computed from IP Revenue / Occupied Bed Days. Higher = better bed monetisation.

🎯 FY24 Baseline → FY27 Target: ₹397 Cr → ₹550 Cr (+38%) | First 100 Days: Operational Efficiency & Revenue Leakage Plug

Two-phase approach: Phase 1 (Days 1–100) — Zero-capex wins through discount discipline, ALOS optimisation, OP-to-IP conversion, and pharmacy capture. Estimated ₹8–14 Cr recoverable with no new investment. Phase 2 (Month 4+) — Structural growth via oncology scaling, liver transplant, insurance penetration, and specialty depth.

⌛ First 100 Days — Operational Efficiency & Revenue Leakage Plug

Discount Leakage

₹5.52 Cr

1.4% of gross billing · partially recoverable

Refunds Issued

₹1.57 Cr

0.4% of billing · process quality signal

Pharmacy Capture

₹34.15 Cr

8.6% of revenue · benchmark is 14–18%

Cash Payor Concentration

73.3%

₹291 Cr cash vs ₹88 Cr insurance

Revenue Seasonality Gap

₹7.94 Cr

May peak ₹38.65 Cr vs Oct trough ₹30.72 Cr

💧 Revenue Leakage Map — FY24 Actuals

Gross billing to net collected. Each layer is a recoverable opportunity.

📉 Discount % by Department — Top Offenders

Emergency Dept at 24.2% discount rate (₹82.5L lost) is the top concern. Nephrology ₹71.9L despite only 1.1% rate — sheer volume.

📈 Monthly Discount Trend (₹ Lakhs)

Discounts accelerated in Oct–Dec (₹47–65L/month). Q3 spike needs investigation — possible year-end clearing or tariff gaps.

🔄 OP-to-IP Conversion Opportunity

High-visit departments with very low admission rates — each 1% conversion improvement = significant IP revenue lift.

100-Day Action Plan — Leakage Plug & Efficiency Initiatives

All actions are zero-to-low capex. Sequenced by speed of impact and ease of implementation.

Day	Initiative	Data Signal	Specific Action	Owner	Revenue Impact	Effort
1–15	Emergency Dept Discount Audit	ED discount rate = 33.3% on ₹2.48 Cr billing = ₹82.6L lost. Highest in hospital.	Freeze ad-hoc ED discounts. Implement rate card with CMO approval for exceptions. Review all FY24 ED waiver approvals.	CMO + Revenue Cycle	+₹40–60L	Low
1–15	Doctor-Level Discount Policy	ER Physician: ₹82.5L discounts. ABI ABRAHAM M: ₹57.7L. SUDISH: ₹29.4L. Top 5 doctors account for ₹160L+ in discounts.	Implement tiered discount authority matrix: doctors can authorise up to 2%, HOD up to 5%, CMO for anything above. Monthly reporting dashboard.	CMO + Finance	+₹60–90L	Low
15–30	OB & Gynec Rate Card Audit	OB & Gynec discount = 4.0% = ₹31L lost on ₹7.66 Cr billing. Highest among major IP departments.	Review maternity package pricing vs actual cost. Rationalise concessions. Identify institutional vs individual discounts.	HOD OB + Finance	+₹15–25L	Low
15–45	Pharmacy Leakage Recovery	Pharmacy = ₹34.15 Cr (8.6% of revenue). Benchmark for tertiary hospitals = 14–18%. Gap = ₹21–37 Cr of uncaptured pharmacy revenue.	Audit discharge prescriptions — are patients buying outside? Implement in-hospital dispensing compliance tracking. OPD prescription capture rate target: 80%+.	Pharmacy Head + Ops	+₹5–8 Cr	Medium
30–60	Refund Process Tightening	Total refunds = ₹1.57 Cr. Med Oncology: ₹36.9L refunds (0.7%). Gastroenterology: ₹11.1L. Signals billing errors or tariff disputes.	Root cause analysis of top 20 refund events per department. Identify billing system gaps. Pre-auth for high-value procedures. Target: reduce refunds by 30%.	Revenue Cycle + HODs	+₹40–50L	Medium
45–75	ALOS Optimisation — Nephrology & Psychiatry	Nephrology ALOS = 9.8 days (peer benchmark 6–7d). Psychiatry ALOS = 12.4 days. Each 1-day ALOS reduction in Nephrology frees ~450 bed days = ₹1.6 Cr throughput gain at current ARPOB.	Implement clinical pathway reviews for Nephrology top DRGs. Establish discharge planning from Day 1 of admission. Weekly LOS monitoring by consultant.	HOD Nephrology + Clinical Ops	+₹1.5–3 Cr	Medium
45–75	OP-to-IP Conversion — Endocrinology & Dermatology	Endocrinology: 11,232 OP visits, only 31 admissions (0.3% conversion). Dermatology: 12,984 OP visits, 24 admissions (0.2%). Both are chronic disease specialties with high admission potential.	Set up dedicated IP admission protocol for chronic cases. Coordinate with Nephrology for diabetic nephropathy pathway. Dermatology: target psoriasis/autoimmune inpatient program. Target: 1% conversion = ~240 additional admissions.	HOD Endocrinology + Dermatology	+₹1–2 Cr	Medium
60–100	Revenue Seasonality Smoothing	Oct–Nov revenue trough = ₹30.7–31.3 Cr vs May peak of ₹38.7 Cr. ₹7.9 Cr variance annually. Occupancy dips in lean months.	Introduce packages for preventive health checks, elective procedures, and wellness programs specifically timed for Q2–Q3. Corporate tie-ups for annual health screenings. Target: reduce trough-to-peak variance by 30%.	Marketing + Business Dev	+₹1–2 Cr	Medium
75–100	Payor Mix — Insurance Quick Wins	Insurance = 22.2% of revenue (₹88.3 Cr) vs Cash 73.3% (₹291 Cr). Apollo at 45% insurance. ₹88 Cr gap vs peer benchmark at current revenue scale.	Fast-track empanelment with 5 top TPAs not yet on panel. Assign dedicated TPA coordinator. Target pre-auth turnaround <4 hours. Set up insurance help desk at registration.	CFO + Revenue Cycle	+₹3–5 Cr	Medium

💰 Total 100-Day Recoverable Revenue Estimate

Conservative: ₹8–12 Cr | Optimistic: ₹14–20 Cr | All zero-to-low capex. Discount discipline alone (₹1–1.5 Cr) and pharmacy leakage (₹5–8 Cr) are the two biggest wins. These flow directly to EBITDA margin improvement.

🚀 Phase 2 — Structural Growth Initiatives (Month 4 onwards)

Revenue Bridge — FY24 to FY27 (₹ Cr)

How ₹397 Cr grows to ₹550 Cr: leakage plug + organic + strategic expansion

Specialty Growth Opportunity Matrix

Bubble size = current revenue. Position = growth potential vs investment required.

Strategic Growth Action Plan — Phase 2

Sequenced by revenue impact. Each initiative has a clear data-backed rationale from FY24 actuals.

Priority	Initiative	FY24 Baseline	Key Data Signal	Action	Rev Impact	Timeline
P1	Oncology Scaling	₹54.91 Cr dept, 5,264 disc	Highest volume dept. No LINAC on campus — radiation patients referred out. Each referred case = ₹1–3L lost.	Commission LINAC. Recruit 2nd oncologist. Target 7,000 disc/yr by FY27. Expand Radiation Oncology from ₹5.98 Cr to ₹20 Cr+.	+₹25–35 Cr	6–18 months
P1	Liver Transplant Programme	₹13.82 Cr, 292 disc	ARPP-IP = ₹4.45L — highest in hospital. Only 292 discharges vs potential 600+. Each transplant = ₹8–15L.	Add 2nd hepatologist. Expand dedicated liver ICU from 6 to 12 beds. Pan-India patient referral network. Target 500+ disc/yr.	+₹20–30 Cr	3–9 months
P2	Insurance Penetration	22.2% insurance mix (₹88.3 Cr)	Cash 73.3% vs Apollo 45%. ₹88 Cr gap to peer benchmark. Each 5% shift from cash to insurance = ₹8–10 Cr incremental at better ARPP.	Empanel 10+ new TPAs. Dedicated insurance coordinator. Pre-auth automation. Corporate wellness contracts. Target: 40% insurance by FY27.	+₹18–25 Cr	6–12 months
P2	Nephrology BMT Expansion	₹66.18 Cr, ARPP-IP ₹3.48L	Top revenue dept. ALOS 9.8d (above peers). BMT programme would attract high-complexity, high-ARPP cases. Bone marrow transplant = ₹15–25L per case.	BMT unit setup (₹35 Cr capex). Target 50 BMT cases/yr in Year 1, 150 by Year 3. Reduce general nephrology ALOS by 2 days through clinical pathways.	+₹15–20 Cr	12–24 months
P2	GI Surgery Robotic Programme	₹26.17 Cr, ARPP-IP ₹1.96L	ARPP-IP ₹1.96L is strong but ALOS 6.4d is high. Robotic surgery reduces ALOS by 1.5–2d and commands 20–30% premium on procedure fees.	Acquire robotic surgery system. Credential 2 surgeons. Target 300 robotic procedures/yr. Reduces ALOS and attracts premium payers.	+₹10–15 Cr	6–12 months
P2	ARPOB Improvement Programme	₹31,898/day vs Apollo ₹60,588	₹28,690/day gap to Apollo. Each ₹5K ARPOB improvement across 93,495 bed-days = ₹4.67 Cr. Case mix upgrade is the primary lever.	Reduce low-ARPP admissions (Psychiatry ₹52K ARPOB, Gen Medicine ₹14K). Grow high-ARPP beds (Liver ₹63K, Nuclear Med ₹46K, Nephrology ₹35K). Target ₹38K ARPOB by FY27.	+₹5–10 Cr	12–18 months
P3	Nuclear Medicine & PET-CT	₹1.06 Cr, 83 admissions	ARPOB ₹46K — 2nd highest in hospital. 3,446 OP visits but nearly zero admissions. PET-CT is a natural feeder for Oncology pathway.	Dedicate PET-CT slot for Oncology patients. Integrate Nuclear Med into cancer care bundles. Target 600+ PET-CT scans/yr. Partner with Radiation Oncology for DOTATATE therapy.	+₹5–8 Cr	6–12 months
P3	ENT Expansion	₹4.07 Cr, 8,085 OP visits	8,085 OP visits but only 304 admissions (3.8% conversion). Strong OP demand not converting. Cochlear implants = ₹3–5L per case.	Add cochlear implant programme. Expand ENT theatre capacity. Target 500+ admissions/yr. ENT OP-to-IP conversion target: 6%.	+₹3–5 Cr	6–12 months

⚠️ Key Risk Register

Top 5 Risks to Revenue Plan

Risk	Current Exposure	Probability	Mitigation
Key Person — GANGADHARAN VP	₹54.46 Cr = 13.7% of revenue	High	Recruit 2nd oncologist. Build department not person. Implement succession plan.
Key Person — ABI ABRAHAM M	₹54.35 Cr = 13.7% of revenue	High	BMT programme reduces single-doctor dependency in Nephrology.
Insurance Claim Rejections	₹1.57 Cr refunds; unclear rejection rate	Medium	Pre-auth automation. Daily TPA rejection tracker. Revenue cycle team.
ALOS vs Bed Capacity	Nephrology ALOS 9.8d blocks beds	Medium	Clinical pathway implementation. Early discharge planning protocol.
Q3 Revenue Dip	Oct–Nov ₹7.9 Cr below peak	Low	Preventive health packages, corporate screenings in lean months.

Implementation Dashboard — 100-Day Tracker

Initiative	Target	Metric	Status
Discount policy	Day 15	ED discount <5%	Not started
Doctor discount matrix	Day 15	Top-10 doc disc <1%	Not started
OB & Gynec rate card	Day 30	Disc <2%	Not started
Pharmacy capture	Day 45	OPD Rx capture >80%	Not started
Refund root cause	Day 60	Refunds <₹1 Cr/yr	Not started
Nephrology ALOS	Day 75	ALOS <8.5d	Not started
TPA empanelment	Day 100	5 new TPAs	Not started
Endocrinology OP-IP	Day 100	Conversion >1%	Not started

LHRC ARPOB

₹31.9K/day

vs Apollo ₹60.6K · gap ₹28.7K

LHRC Occupancy

54.4%

vs Apollo 68% · IHH 72% · 471 beds

LHRC ALOS

4.47 days

vs Apollo 3.32d · IHH 4.2d

LHRC EBITDA (target)

19%

vs Apollo 24.6% · IHH 18%

LHRC ARPP-IP

₹1.42 L

vs Apollo ₹1.73 L · gap ₹31,000

Insurance Mix

22.2%

vs Apollo 45% · IHH 35%

ARPOB — ₹/Occupied Bed/Day

Gap: LHRC ARPOB ₹31,875 is 47% below Apollo ₹60,588. Closing to ₹38K would add ~₹5.7 Cr annually at current bed days.

Bed Occupancy Rate (%)

Gap: 13-18 ppt occupancy gap vs peers. Each 5 ppt improvement = ~8,600 occupied bed days = ~₹2.7 Cr at ARPOB ₹31,875.

ALOS — Average Length of Stay (Days)

Near parity: LHRC 4.47d vs IHH India 4.2d vs Apollo 3.32d. Oncology and Nephrology long stays pull the average up.

Specialty Mix vs Apollo — % of IP Revenue

Insight: LHRC Nephrology at 17.4% is unusually high. Apollo shows Neuro 10% and Gastro 10% — both growth opportunities for LHRC.

Payor Mix — LHRC vs Apollo vs IHH

EBITDA Margin (%)

Apollo's playbook: Reached 24.6% by (1) upgrading case mix, (2) reducing ALOS, (3) expanding pharmacy. LHRC at 19% target — same levers available.

Detailed Benchmark Comparison Table

Metric	LHRC FY24	IHH India FY24	Apollo FY25/H1FY26	LHRC Gap vs Apollo
Operational Beds	471	5,008 (28 hospitals)	8,025 (45 hospitals)	Different scale
Occupancy Rate	54.4%	72%	68%	▼ 15.3 ppt
ALOS (days)	4.47	4.2	3.32	▲ 1.5d longer
ARPOB (₹/day)	₹31,875	~₹47,100	₹60,588	▼ ₹33,903
ARPP-IP	₹1.42 L	~₹1.96 L (RM 9,902)	₹1.73 L	▼ ₹44,000
EBITDA Margin	~19% (target)	18%	24.6%	▼ 5.6 ppt
Insurance % (Payor)	22.2%	~35%	45%	▼ 19 ppt
Revenue Growth YoY	~12% (plan)	13% (FY24)	9-10%	On track

📋 Department / Doctor MIS — Monthly Breakdown

Select a doctor to view month-wise IP Revenue, OP Revenue & KPIs · Amount in Lakhs · Source: Taxable Amt · Kochi FY24

Department

Doctor

Search

All Doctors — FY24 Annual Summary (click any row to load detail)

# Doctor	Department	Total (L) ▼	IP (L)	OP (L)	IP Disc.	Bed Days	OP Visits	ARPP(OP)	ARPP(IP)	ARPOB